The class action solicitations are gonna be flying off the newswires. Wish I had such an ignore feature in my market news feed.
I read Cassava's public response this morning; they'll have to be more forthcoming with the FDA. E.g., there was a serious mismatch between table and chart and the company's response was "the table's correct". That's not an explanation. If that chart is part of an FDA submission, they won't take that for an answer.
I wonder when the FDA will decide on the requested trial halt. That's Cassava's immediate concern. At $4.7B MC, their share price has a long way to fall on this kind of news. Luckily they have a quarter billion in net cash, which is plenty for now.
Market Data 
Markets 
